Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework

Table 1 Modelled vaccine’s efficacy per disease and costs per case

Disease	Vaccine efficacy^a (1)	Proportion attributable to HPV 6/11/16/18^b (2)	Model’s efficacy (1) × (2)	Cost per case
GW	Females 99 %; 89 % for males	90 %	Females 89 %; males 81 %	€550	[2]
CIN I	98 %	35 %	34.3 %	€336	[6]
CIN II	98 %	55 %	53.9 %	€336
CIN III	97 %	55 %	53.3 %	€1,498
Cervical cancer	100 %	76 %	76 %	€12,499
Anal cancer	87 %	79 %	68.7 %	Females €25,097; males €29,473	[4]
Vulvar cancer	100 %	37 %	37 %	€12,499	(Equal to cervical cancer cost)
Vaginal cancer	100 %	61 %	61 %	€12,499	(Equal to cervical cancer cost)
H&N cancer (in sensitivity analysis)	78-96 % on persistent infection	19 %	18.2 %	Females €16,990; males €18,188	[5]

^aSources for vaccine efficacy. Gardasil SPC; in the absence of clinical data on vaccine’s efficacy against H&N cancers (for which there is currently no indication), efficacy against HPV16/18 persistent infection has been used in sensitivity analysis (no efficacy considered in base case)
^bSources for proportion attributable to HPV 6/11/16/18, [27–33, 1, 34]

ISSN: 2191-1991